Complementing this approach, the augmented expression of TNFAIP3 being investigated in multiple avenues (e.g., SSc, cystic fibrosis) could prove to be productive grounds for dedicated wound healing studies capitalizing on the repurposing of approved or pipeline therapeutics. Here, TNFAIP3 is linked to systemic sclerosis.